Seek Labs Publishes Nature Communications Study Showcasing ANINA™ Technology for Next-Generation Molecular Diagnostics
Seek Labs, a private TechBio company focused on developing programmable technologies to decode, understand, and treat disease, has announced the publication of a peer-reviewed research paper in Nature Communications highlighting its proprietary Annexing Isothermal Nucleotide Amplification (ANINA™) technology. The study describes the scientific foundation of the amplification chemistry that powers the company’s SeekIt™ molecular diagnostic platform, which is being developed to deliver laboratory-quality molecular testing without the need for specialized equipment or complex laboratory infrastructure.
The publication, titled “Annexing Isothermal Nucleotide Amplification (ANINA) Enables Probe-Guided Amplification and Direct Detection at Ambient Temperature,” presents experimental findings demonstrating that ANINA can perform highly sensitive molecular detection using a simplified workflow that operates at room temperature. According to the company, the technology has the potential to bridge the longstanding gap between the analytical performance of molecular diagnostics and the accessibility required for point-of-care, field, and resource-limited settings.
The research also illustrates how the same chemistry can be adapted for high-throughput laboratory environments, offering faster turnaround times than conventional quantitative polymerase chain reaction (qPCR) while maintaining comparable analytical performance.
Addressing Longstanding Challenges in Molecular Diagnostics
Molecular diagnostic testing has become an essential tool for detecting infectious diseases, identifying genetic abnormalities, monitoring treatment response, and supporting precision medicine. However, despite its importance, traditional molecular testing has generally required sophisticated laboratory equipment, temperature-controlled amplification systems, trained laboratory personnel, and multi-step processing workflows.
These requirements often limit access to molecular testing, particularly in decentralized healthcare settings, rural communities, emergency situations, and regions with limited laboratory infrastructure.
According to Seek Labs, ANINA was developed to overcome these limitations by fundamentally rethinking how molecular amplification and detection are performed.
Rather than adapting existing molecular technologies into smaller instruments, the company designed a new amplification chemistry capable of integrating multiple diagnostic functions into a single reaction that operates under ambient conditions.
Introducing ANINA™ Amplification Chemistry
ANINA™, short for Annexing Isothermal Nucleotide Amplification, serves as the core technology behind the SeekIt molecular diagnostic platform.
Unlike traditional molecular amplification methods that require repeated heating and cooling cycles, ANINA performs amplification using an isothermal approach, allowing reactions to proceed at a constant temperature.
More significantly, the technology incorporates a novel probe-guided mechanism in which the probe participates directly in both amplification and detection.
This eliminates several processing steps commonly required in conventional molecular assays.
According to the published research, ANINA performs the complete molecular testing process—including target recognition, amplification, and result generation—in a single reaction.
Because the detection probe remains attached throughout amplification, positive or negative results can be read directly using a simple lateral-flow paper strip without requiring additional enzymes, post-amplification processing, specialized heating equipment, or separate detection reactions.
Powering the SeekIt™ Diagnostic Platform
The company’s SeekIt™ molecular diagnostic platform has been built around ANINA technology.
Traditional molecular diagnostic workflows generally involve four essential stages:
- Target identification
- Target capture
- Amplification
- Result detection
Each stage often requires different reagents, specialized instrumentation, and laboratory expertise.
Seek Labs designed SeekIt to integrate these four functions into one streamlined molecular testing platform.
By combining all critical testing steps into a simplified workflow, SeekIt aims to deliver laboratory-grade molecular diagnostics in environments where conventional laboratory testing may not be practical.
Although the platform remains under development, the underlying chemistry represents a significant departure from traditional diagnostic approaches.
Company Leadership Highlights Innovation
Jared Bauer, Chief Executive Officer and Co-Founder of Seek Labs, explained that molecular diagnostics have historically required healthcare providers to balance analytical performance with accessibility.
Highly accurate laboratory tests often require sophisticated infrastructure, while simpler point-of-care tests may sacrifice sensitivity or specificity.
According to Bauer, ANINA fundamentally changes this equation by delivering molecular-level performance without laboratory equipment.
He noted that the technology provides the analytical sensitivity and specificity associated with molecular testing while operating in a format requiring neither specialized instruments nor laboratory facilities.
At the same time, Bauer emphasized that ANINA also offers benefits for centralized laboratories, where it can operate on standard laboratory equipment at speeds reportedly two to four times faster than conventional qPCR workflows.
Scientific Perspective on the Technology
Dr. Annie Roy, Vice President of Diagnostic Research at Seek Labs and corresponding author of the Nature Communications publication, described ANINA as a true chemistry innovation rather than simply a smaller diagnostic device.
She explained that the development effort focused on determining whether molecular tests could combine the analytical accuracy of qPCR with the operational simplicity associated with rapid antigen testing.
According to Roy, confidence in the technology emerged from its consistent performance across multiple pathogens, sample types, and testing conditions.
She noted that successful application across bacteria, viruses, and different biological matrices suggests ANINA may serve as a versatile molecular testing platform for diverse healthcare applications.
Potential future applications include:
- Human healthcare
- Veterinary medicine
- Global public health
- Biosecurity
- Infectious disease surveillance
Broad Evaluation Across Multiple Pathogens
The Nature Communications study evaluated ANINA across several infectious organisms representing different pathogen categories.
The publication examined detection performance for:
- White Spot Syndrome Virus (WSSV)
- Epstein-Barr Virus (EBV)
- Respiratory Syncytial Virus (RSV)
- Neisseria gonorrhoeae
These organisms include DNA viruses, an RNA virus, and a bacterial pathogen.
Researchers tested the amplification chemistry using multiple biological sample types, including:
- Shrimp tissue
- Pooled human saliva
- Simulated human urine
This diversity of pathogens and specimen matrices allowed investigators to evaluate the flexibility and robustness of the technology across different diagnostic scenarios.
Multiple Detection Formats
The study further demonstrated that ANINA supports multiple readout approaches.
Positive amplification results were confirmed using:
- Instrument-free lateral-flow paper strips
- Real-time fluorescence detection on standard qPCR instruments
This dual compatibility allows the chemistry to function in both decentralized testing environments and conventional laboratory settings.
Healthcare providers operating outside laboratory facilities may utilize paper-strip detection, while centralized laboratories may integrate ANINA into existing fluorescence-based workflows.
Key Findings from the Study
According to the published research, ANINA demonstrated several notable analytical capabilities.
High Sensitivity
Researchers reported detection of as few as one to ten copies of viral DNA within human saliva samples.
Such sensitivity may enable identification of infection during very early stages when pathogen concentrations remain extremely low.
Early detection is particularly valuable for infectious disease management because intervention may occur before symptoms worsen or transmission increases.
High Specificity
The technology also demonstrated accurate identification of Neisseria gonorrhoeae within simulated urine samples.
Importantly, investigators reported no false-positive results during these evaluations, indicating strong analytical specificity.
Equipment-Free Operation
One of ANINA’s defining features is its ability to perform molecular testing at room temperature without laboratory instruments.
Results were generated using only disposable paper strips, eliminating dependence on powered laboratory equipment.
This capability may significantly expand access to molecular diagnostics in resource-limited environments.
Faster Laboratory Performance
When operated using standard laboratory fluorescence instrumentation, ANINA reportedly matched the quantitative analytical performance of qPCR while producing results two to four times faster.
Shorter testing times may improve laboratory throughput during periods of high testing demand.
Detection in Natural Infection
Researchers also evaluated ANINA using shrimp naturally infected with White Spot Syndrome Virus.
According to the publication, the technology detected early-stage infection within 45 minutes using only disposable testing components and no powered laboratory equipment.
Investigators reported that ANINA outperformed a commercially available rapid antigen test when analyzing identical samples.
Potential Applications Beyond Healthcare
Although healthcare diagnostics remain an important focus, Seek Labs believes ANINA may have applications extending well beyond traditional clinical medicine.
Potential future use cases include:
- Pandemic preparedness
- Disease surveillance
- Veterinary diagnostics
- Agricultural health
- Food safety
- Environmental monitoring
- National biosecurity
Because the platform can potentially function without sophisticated laboratory infrastructure, it may support testing in locations where rapid molecular diagnostics have historically been difficult to deploy.
Current Development Status
Despite the encouraging research findings, Seek Labs emphasized that the SeekIt molecular diagnostic platform remains under development.
The company noted several important regulatory considerations.
Specifically:
- SeekIt has not been authorized or cleared by the U.S. Food and Drug Administration for clinical diagnostic use.
- Human pathogen experiments described in the publication were conducted using contrived sample matrices rather than clinical patient specimens.
- ANINA has not yet undergone human clinical evaluation.
Additional clinical validation studies will be necessary before the technology can be considered for regulatory review and potential commercialization.
Future Development Plans
Building upon the findings reported in Nature Communications, Seek Labs plans to initially focus development of the SeekIt platform on respiratory disease diagnostics and biosecurity applications.
These areas were selected because rapid molecular testing performed outside conventional laboratories could have a meaningful impact on disease detection, outbreak response, and public health decision-making.
The company believes decentralized access to highly sensitive molecular testing could improve diagnostic speed while expanding availability in settings where traditional laboratory testing remains impractical.
The publication of ANINA research in Nature Communications represents an important scientific milestone for Seek Labs and highlights the company’s efforts to transform molecular diagnostics through innovative amplification chemistry. By integrating target recognition, amplification, and detection into a single room-temperature reaction, ANINA has the potential to simplify molecular testing while maintaining the analytical sensitivity and specificity associated with laboratory-based methods.
Although the SeekIt™ platform remains in development and has not yet received regulatory authorization for clinical use, the preclinical findings demonstrate promising performance across multiple pathogens, biological sample types, and detection formats. As Seek Labs continues advancing clinical validation and regulatory development, the company aims to expand access to rapid, laboratory-independent molecular diagnostics that could benefit healthcare providers, public health agencies, veterinary medicine, and biosecurity programs. If future studies confirm these early results, ANINA may represent a significant step forward in making high-performance molecular testing more accessible, scalable, and practical across a broad range of real-world applications.
About SeekIt™
SeekIt is Seek Labs’ molecular point-of-care diagnostic platform designed to bring testing out of laboratories and to the point of care. Built for speed, accuracy, portability, and scalability, SeekIt integrates Annexing Isothermal Nucleotide Amplification (ANINA™), the company’s patented amplification chemistry with sample extraction and lateral-flow detection into a streamlined system designed for rapid deployment across clinical, public health, and field environments.
About Seek Labs
Every disease has a sequence. Seek Labs is a TechBio company building the systems to decode, program, and resolve diseases. At the core of this system is an AI-powered intelligence layer that analyzes and translates sequences into actionable data, informing two deployment layers across Sequence Ablation Therapeutics (SAT) and molecular detection. Together, these systems form a continuous loop where genomic data is decoded, translated into therapeutic and diagnostic outputs, and refined through real-world deployment.
Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.